Roche Holding AG Other Current Assets 2010-2023 | RHHBY
Roche Holding AG other current assets from 2010 to 2023. Other current assets can be defined as field containing the sum of all current assets that cannot be standardized into another field as well as those that are aggregated by the company because materially, they are too small to list separately.
- Roche Holding AG other current assets for the quarter ending December 31, 2023 were $4.641B, a 33.13% increase year-over-year.
- Roche Holding AG other current assets for 2023 were $3.87B, a 3.78% decline from 2022.
- Roche Holding AG other current assets for 2022 were $4.022B, a 9.79% decline from 2021.
- Roche Holding AG other current assets for 2021 were $4.458B, a 28.22% increase from 2020.
Roche Holding AG Annual Other Current Assets
(Millions of US $) |
| 2023 |
$3,870 |
| 2022 |
$4,022 |
| 2021 |
$4,458 |
| 2020 |
$3,477 |
| 2019 |
$2,920 |
| 2018 |
$2,790 |
| 2017 |
$2,633 |
| 2016 |
$2,919 |
| 2015 |
$3,157 |
| 2014 |
$2,916 |
| 2013 |
$2,715 |
| 2012 |
$2,532 |
| 2011 |
$2,362 |
| 2010 |
$2,245 |
| 2009 |
$3,529 |
Roche Holding AG Quarterly Other Current Assets
(Millions of US $) |
| 2023-12-31 |
$4,641 |
| 2022-12-31 |
$4,022 |
| 2022-06-30 |
$4,569 |
| 2021-12-31 |
$4,458 |
| 2021-06-30 |
$3,486 |
| 2020-12-31 |
$3,477 |
| 2020-06-30 |
$3,111 |
| 2019-12-31 |
$2,920 |
| 2019-06-30 |
$2,803 |
| 2018-12-31 |
$2,790 |
| 2018-06-30 |
$2,898 |
| 2017-12-31 |
$2,633 |
| 2017-06-30 |
$2,865 |
| 2016-12-31 |
$2,919 |
| 2016-06-30 |
$2,830 |
| 2015-12-31 |
$3,157 |
| 2015-06-30 |
$3,086 |
| 2014-12-31 |
$2,916 |
| 2014-06-30 |
$3,008 |
| 2013-12-31 |
$2,715 |
| 2013-06-30 |
$2,572 |
| 2012-12-31 |
$2,532 |
| 2012-06-30 |
$2,681 |
| 2011-12-31 |
$2,362 |
| 2011-06-30 |
$3,479 |
| 2010-12-31 |
$2,245 |
| 2010-06-30 |
$2,528 |
| 2009-12-31 |
$3,529 |
| 2009-06-30 |
$3,488 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Large Cap Pharmaceutical |
$247.847B |
$65.370B |
|
Basel, Switzerland-based Roche Holding Ltd. is a leading health care company focused on developing and commercializing innovative diagnostic and therapeutic products and services, which enable early detection and prevention of diseases as well as their treatment and monitoring. The company conducts its operations through two segments ' Pharmaceuticals and Diagnostics.Pharmaceuticals: Key focus areas in this segment include Oncology, Virology, Inflammation, Metabolism and Neuroscience. Diagnostics: The Diagnostics Division operates in four segments ' Roche Professional Diagnostics, Roche Diabetes Care, Roche Molecular Diagnostics, and Roche Tissue Diagnostics. In September 2014, Roche acquired InterMune for $8.3 billion and added Esbriet to its portfolio. During the first quarter of 2018, Roche acquired Flatiron Health and Ignyta, Inc.
|
